In recent years, extensive genomic characterization has revealed various actionable mutations in lung cancer, including epidermal growth factor receptor (EGFR), Kirsten rat sarcoma virus (KRAS), and anaplastic lymphoma kinase (ALK) mutations [15]. This evidence concerns the gene KRAS and lung cancer.